An X-Linked Hyper-IgM Patient Followed Successfully for 23 Years without Hematopoietic Stem Cell Transplantation.

Pub Date : 2018-10-14 eCollection Date: 2018-01-01 DOI:10.1155/2018/6897935
Necil Kutukculer, Neslihan Edeer Karaca, Guzide Aksu, Ayca Aykut, Erhan Pariltay, Ozgur Cogulu
{"title":"An X-Linked Hyper-IgM Patient Followed Successfully for 23 Years without Hematopoietic Stem Cell Transplantation.","authors":"Necil Kutukculer,&nbsp;Neslihan Edeer Karaca,&nbsp;Guzide Aksu,&nbsp;Ayca Aykut,&nbsp;Erhan Pariltay,&nbsp;Ozgur Cogulu","doi":"10.1155/2018/6897935","DOIUrl":null,"url":null,"abstract":"<p><p>When caring for patients with life-limiting diseases, improving survival and optimizing quality of life are the primary goals. For patients with X-linked hyper-IgM syndrome (XHIGM), the treatment modality has to be decided for a particular patient regarding hematopoietic stem cell transplantation or intravenous immunoglobulin replacement therapy with <i>P. jiroveci</i> prophylaxis. A seven-year-old male patient was admitted with recurrent upper and lower respiratory tract infections and recurrent otitis media. His initial immunologic evaluation revealed low IgG and normal IgA and IgM levels with normal lymphocyte phenotyping and inadequate specific antibody responses. He was diagnosed as common variable immunodeficiency and began to receive intravenous immunoglobulin (IVIG) (0.5 gm/kg) with four-week intervals. During follow-up for 23 years under IVIG therapy, he was extremely well and never had severe infections. In 2017, targeted next generation sequencing was performed in order to understand his molecular pathology. A previously described hemizygous c.31C>T(p.Arg11Ter) mutation was found in <i>CD40LG</i> gene. The mother was heterozygous carrier for this mutation and his sister did not have any mutation. Flow cytometric analysis for <i>CD40LG</i> expression on activated T cells showed highly decreased, but not absent, <i>CD40LG</i> expression. In conclusion, diagnostic delay is a clinical problem for patients with <i>CD40LG</i> deficiency, because of low or normal IgM levels, showing that all the hypogammaglobulinemic patients, not only with high serum IgM levels, but also with normal to low IgM levels, have to be examined for <i>CD40LG</i> expression on activated T lymphocytes. Secondly, type of <i>CD40LG</i> mutations leads to enormous interpatient variations regarding serum IgM levels, CD40LG levels on activated T cells, age at diagnosis, severity of clinical findings, and follow-up therapies with or without hematopoietic stem cell therapy.</p>","PeriodicalId":0,"journal":{"name":"","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2018/6897935","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2018/6897935","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

When caring for patients with life-limiting diseases, improving survival and optimizing quality of life are the primary goals. For patients with X-linked hyper-IgM syndrome (XHIGM), the treatment modality has to be decided for a particular patient regarding hematopoietic stem cell transplantation or intravenous immunoglobulin replacement therapy with P. jiroveci prophylaxis. A seven-year-old male patient was admitted with recurrent upper and lower respiratory tract infections and recurrent otitis media. His initial immunologic evaluation revealed low IgG and normal IgA and IgM levels with normal lymphocyte phenotyping and inadequate specific antibody responses. He was diagnosed as common variable immunodeficiency and began to receive intravenous immunoglobulin (IVIG) (0.5 gm/kg) with four-week intervals. During follow-up for 23 years under IVIG therapy, he was extremely well and never had severe infections. In 2017, targeted next generation sequencing was performed in order to understand his molecular pathology. A previously described hemizygous c.31C>T(p.Arg11Ter) mutation was found in CD40LG gene. The mother was heterozygous carrier for this mutation and his sister did not have any mutation. Flow cytometric analysis for CD40LG expression on activated T cells showed highly decreased, but not absent, CD40LG expression. In conclusion, diagnostic delay is a clinical problem for patients with CD40LG deficiency, because of low or normal IgM levels, showing that all the hypogammaglobulinemic patients, not only with high serum IgM levels, but also with normal to low IgM levels, have to be examined for CD40LG expression on activated T lymphocytes. Secondly, type of CD40LG mutations leads to enormous interpatient variations regarding serum IgM levels, CD40LG levels on activated T cells, age at diagnosis, severity of clinical findings, and follow-up therapies with or without hematopoietic stem cell therapy.

Abstract Image

分享
查看原文
一名x连锁超igm患者成功随访23年,未进行造血干细胞移植。
在对患有限制性疾病的患者进行护理时,提高生存率和优化生活质量是首要目标。对于x连锁高igm综合征(XHIGM)患者,治疗方式必须根据患者的具体情况来决定,是采用造血干细胞移植还是静脉注射免疫球蛋白替代治疗,同时采用预防罗氏疟原虫的方法。一名七岁男童因反复上呼吸道感染及反复中耳炎而入院。他最初的免疫评估显示IgG低,IgA和IgM水平正常,淋巴细胞表型正常,特异性抗体反应不足。他被诊断为常见的可变免疫缺陷,并开始接受静脉注射免疫球蛋白(IVIG) (0.5 gm/kg),间隔4周。在接受IVIG治疗的23年随访期间,他非常好,从未发生过严重感染。2017年,为了了解他的分子病理,我们进行了靶向下一代测序。在CD40LG基因中发现了先前描述的半合子c.31C>T(p.Arg11Ter)突变。母亲是这种突变的杂合携带者,而他的妹妹没有任何突变。流式细胞术分析活化T细胞的CD40LG表达,显示CD40LG表达高度降低,但并非完全缺失。综上所述,由于IgM水平低或正常,CD40LG缺乏症患者的诊断延迟是一个临床问题,这表明所有低γ球蛋白血症患者,不仅是血清IgM水平高的患者,而且是IgM水平正常到低的患者,都必须检查活化T淋巴细胞上CD40LG的表达。其次,CD40LG突变的类型导致患者之间在血清IgM水平、活化T细胞上的CD40LG水平、诊断年龄、临床表现的严重程度以及接受或不接受造血干细胞治疗的后续治疗方面存在巨大差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信